BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AtheroGenics (AGIX) Restructures Board of Directors


9/11/2008 7:02:43 AM

ATLANTA, GA--(MARKET WIRE)--Sep 10, 2008 -- AtheroGenics, Inc. (AGIX - News), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it has restructured its Board of Directors to reduce the number of directors from ten to six in order to better align the size of its Board with the current needs of the Company. Remaining on the Board will be:

Michael A. Henos Chairman of the Board, AtheroGenics, Inc. Managing Partner, Alliance Technology Ventures, L.P.

R. Wayne Alexander, M.D., Ph.D. Chairman, Department of Medicine Emory University School of Medicine

Samuel L. Barker, Ph.D. Founder, Clearview Projects, Inc.

Vaughn D. Bryson Retired President and Chief Executive Officer Eli Lilly and Company

Margaret E. Grayson President, Coalescent Technologies

Russell Medford, M.D., Ph.D. President and Chief Executive Officer, AtheroGenics, Inc.

"We believe that the new AtheroGenics' Board continues to provide the expertise and experience to guide our Company going forward and to maximize value for all of our varied stakeholders," said Michael A. Henos, Chairman of the AtheroGenics Board of Directors.

In connection with the Board restructuring, David Bearman, T. Forcht Dagi, M.D., Arthur M. Pappas and William A. Scott, Ph.D., resigned from the Board of Directors. Mr. Henos commented, "We want to thank the departing Board members for their hard work and contributions to the Company."

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease (atherosclerosis). The Company's lead antioxidant and anti-inflammatory drug candidate, AGI-1067, is being studied for the treatment of diabetes and has completed a Phase 3 clinical trial known as ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study). In addition, the Company has other clinical and preclinical anti-inflammatory compounds, including AGI-1096, an oral agent for the prevention of organ transplant rejection. For more information about AtheroGenics, please visit http://www.atherogenics.com.

Contact: Source: AtheroGenics, Inc.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES